(Q40439768)

20 September 2017

A Case of Septic Shock Due to Serratia marcescens Pyelonephritis and Bacteremia in a Patient Receiving Empagliflozin (English)

1 reference

20 September 2017

0 references

1 reference

1 reference

Serratia marcescens

1 reference

Wesley D Kufel

1

1 reference

20 September 2017

Ali Scrimenti

series ordinal

2

1 reference

20 September 2017

Jeffrey M Steele

series ordinal

3

1 reference

20 September 2017

21 November 2016

1 reference

Journal of Pharmacy Practice

20 September 2017

1 reference

Standards of Medical Care in Diabetes-2016 Abridged for Primary Care Providers

20 September 2017

1 reference

https://api.crossref.org/works/10.1177%2F0897190016679760

Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190016679760

A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190016679760

Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190016679760

Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190016679760

SGLT2 inhibition: efficacy and safety in type 2 diabetes treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190016679760

Genital and urinary tract infections in diabetes: impact of pharmacologically-induced glucosuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190016679760

21 January 2018

Identifiers

DOI

10.1177/0897190016679760

0 references

1 reference